Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | Inquiry | Backorder | |
5 mg | Inquiry | Backorder |
Description | Bapotulimab (BAY-1905254) is a fully human IgG2 antibody targeting the immunoglobulin-like domain-containing receptor 2 (ILDR2), and it exhibits antitumor and immunosuppressive effects [1]. |
In vitro | Bapotulimab inhibits the immunosuppressive effect of ILDR2 on T cell activation. This agent exhibits cross-reactivity between humans and mice, attributed to a 98% sequence identity in the extracellular domain between human and murine orthologs of ILDR2 [1]. Bapotulimab (BAY-1905254; at concentrations of 5, 25, 100, or 500 ng/mL) enhances T cell activation and promotes the proliferation of antigen-specific T cells in vitro [1]. |
In vivo | Bapotulimab (BAY-1905254; 10 mg/kg; intraperitoneal injection; administered on days 1 and 4) demonstrated a significant increase in antigen-specific T-cell proliferation and cytotoxicity [1]. |
Alias | BAY-1905254 |
Cas No. | 2359413-58-2 |
Storage |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.